Status:
COMPLETED
Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins
Lead Sponsor:
Gary E. Stein, Pharm.D.
Collaborating Sponsors:
Astellas Pharma US, Inc.
Conditions:
Candidemia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this pharmacokinetic (PK) and pharmacodynamic (PD) study is: To study the rate and duration of serum cidal activity of caspofungin (CFG) and micafungin (MFG) against Candida isolates f...
Detailed Description
Methods: Patients - Adult patients with presumptive candidemia. Patients with severe neutropenia (\<500) APACHE II scores \> 20, or significant liver disease will be excluded. All will give written i...
Eligibility Criteria
Inclusion
- Adult patients with presumptive candidemia
Exclusion
- Patients with severe neutropenia (\<500)
- Patients with APACHE II scores \> 20
- Patients with severe liver disease
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00839540
Start Date
December 1 2008
End Date
May 1 2010
Last Update
April 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sparrow Hospital
Lansing, Michigan, United States, 48912